BrainsWay Gains Significant Payer Support for Nurse Practitioner-Administered Deep TMS Therapy
BWAY has more than doubled off its 52-week low of $3.92.
Summary
BrainsWay announced growing U.S. payer support, including Optum, for nurse practitioners to administer its Deep TMS therapy, significantly expanding patient access and addressing provider capacity constraints.
Key Events · Product Development and Regulatory · BWAY
-
Expanded Payer Coverage
BrainsWay reported a growing trend among U.S. commercial insurers, Medicare Administrative Contractors (MACs), and government payers to cover Transcranial Magnetic Stimulation (TMS) therapy when administered by appropriately trained nurse practitioners.
-
Optum Policy Update
Optum/United Behavioral Health updated its clinical policy in late 2025 to explicitly allow psychiatric mental health nurse practitioners (PMHNPs) to order, supervise, and administer TMS therapy in states with full practice authority, impacting approximately 34.8 million lives.
-
Increased Patient Access
The company's CEO noted that this evolution in payer policy is expected to improve access to Deep TMS, reduce wait times, and help more patients benefit from the clinically proven, non-pharmacologic treatment, especially in areas with psychiatrist shortages.
-
Addresses Capacity Constraints
BrainsWay believes that broader acceptance of nurse practitioner-delivered TMS care will help address provider capacity constraints and support more timely access to treatment.
Analysis · BWAY · Industrial Applications And Services
This 6-K filing highlights a material positive development for BrainsWay, as major U.S. payers are increasingly covering Deep TMS therapy when administered by nurse practitioners. This policy shift, exemplified by Optum's updated coverage for 34.8 million lives, removes a significant structural barrier to treatment access. By expanding the pool of qualified clinicians, BrainsWay can address provider shortages, reduce patient wait times, and potentially accelerate the adoption and revenue growth of its Deep TMS platform. This development strengthens the commercial outlook for the company's core mental health treatment, especially as the stock is currently trading near its 52-week high.
At the time of this filing, BWAY was trading at $14.64 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $595.5M. The 52-week trading range was $3.92 to $15.14. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.